National and European Union-LEVEL Recommendations to Accelerate Vaccine Timely Access

Author(s)

Kapusniak A1, Rémuzat C2, Laigle V3, Beck E3, Toumi M4
1Creativ-Ceutical, Cracow, Poland, 2Creativ-Ceutical, Lyon, France, 3Vaccines Europe Market Access Working Group, Brussels, Belgium, 4Aix Marseille University, Marseille, France

OBJECTIVES: The aim of this study was to identify policy changes required to shorten population access to vaccinations in the European Union (EU).

METHODS: Vaccine experts from exemplar EU countries (France, Germany, Italy, the Netherlands, Poland, Sweden, and the UK) were interviewed to obtain insights into potential policy changes to improve vaccines access in Europe.

RESULTS: Experts recommended enhanced collaboration at the EU level as a key policy change, naming scientific activities and information sharing. They also underlined that joint HTA clinical assessment, and development of vaccine assessment framework guidelines will influence the overall process. The recommended national level changes identified were: 1) National Immunisation Technical Advisory Groups (NITAGs): introduction of formal early advice, systematic involvement of vaccine experts, formalisation of horizon scanning, definition of timelines and prioritisation criteria for the assessment; 2) NITAGs and Health Technology Assessment bodies: roles clarification and decision-making process standardisation, transparency improvement, consideration of vaccination specificities, and increases in vaccines cost-effectiveness threshold (for one exemplar country); 3) Vaccine Companies: communication with healthcare professionals/organisations in charge of vaccination information campaigns, sufficient vaccines stock to ensure proper implementation of vaccination programs, generation of effectiveness data/country-specific data, earlier engagement with authorities and articulation of new vaccines within current vaccination schedules.

CONCLUSIONS: Vaccine experts’ recommendations, on potential future policy changes for improving the Vaccines Access Pathway in Europe, were collected through a stakeholder survey. The outcomes of the study showed the need for a policy change at a national and European level.

Conference/Value in Health Info

2020-11, ISPOR Europe 2020, Milan, Italy

Value in Health, Volume 23, Issue S2 (December 2020)

Code

PIN138

Topic

Epidemiology & Public Health, Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Public Health, Reimbursement & Access Policy, Systems & Structure

Disease

Vaccines

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×